Orthopedic Drives Greatbatch in 2Q - Analyst Blog
August 01 2011 - 10:00AM
Zacks
Greatbatch’s (GB)
second-quarter fiscal 2011 adjusted (excluding one-time
expenses/gains) earnings per share of 43 cents were in line with
the Zacks Consensus Estimate and above the year-ago adjusted
earnings of 40 cents. Profit (as reported) jumped 9.8% year over
year to roughly $8.6 million (or 36 cents a share) owing to higher
sales. The Clarence, New York-based company raised its revenue and
earnings forecast for the full year.
Revenues
Revenues rose 4% year over year to
$146.5 million on the heels of strong growth at the company’s
Orthopedic business backed by favorable foreign exchange
translation impact, offsetting a weak CRM business. Sales topped
the Zacks Consensus Estimate of $141 million. Foreign currency
movements contributed $5 million to
revenues.
Segment Review
Revenues from the larger Greatbatch
Medical division climbed 5% year over year to $126.4 million. Solid
Orthopedic growth was, in part, masked by declines across the
Vascular Access and CRM/Neuromodulation franchises.
CRM/Neuromodulation sales inched
down 1% year over year to $77.7 million, hit by sustained pricing
headwind and general sluggishness in the CRM market.
Orthopedic revenues soared 24% to
$37.9 million, buoyed by customer inventory buildup/product
launches and market share gains which fueled growth across all
product lines. Moreover, favorable foreign exchange swings also
meaningfully contributed to the growth. Greatbatch expects these
factors to continue to boost
orthopedic sales through 2011. Barring the currency impact,
orthopedic revenues jumped 8% in the quarter.
Vascular Access sales fell 2% in
the quarter to $10.8 million, impacted by tough year over year
comparison.
Revenues from Greatbatch’s
Electrochem segment, which offers high performance commercial
batteries, dipped 2% year over year to $20.1 million. While sales
fell in the quarter, the company benefited from customer inventory
rebuilds and healthy energy and environmental market conditions.
Greatbatch
expects seasonality to impact the division’s sales during
the second half.
Margins
Gross margin fell to 31.8% from
32.3% year-ago as revenue growth was partly neutralized by
unfavorable sales mix and pricing concessions made to large
customers. Selling, general and administrative expenses, as a
percentage of sales, rose to 12% from 11.7% in the prior-year
quarter, as a result of higher professional and consulting expenses
and unfavorable currency exchange impact. Adjusted operating margin
declined narrowly to 12.6% from 12.7% a year-ago.
Financial
Health
Greatbatch exited the second
quarter with cash and cash equivalents of roughly $36.9 million,
down 19% year over year. Operating cash flows for the quarter
dipped roughly 43% year over year to $13 million. The company
de-leveraged its balance sheet during the second quarter by
repaying long-term debt worth $20 million. As such, its long-term
debt reduced roughly 8% sequentially (and 22% year over year) to
$205.7 million. Greatbatch plans to continue to use its cash flows
to fund R&D initiatives and pare debt.
Outlook
Based on its first half results and
expectations for the back half, Greatbatch has lifted its top and
bottom line projections for fiscal 2011. The company now expects
revenues between $550 million and $570 million compared with its
earlier forecast of $540 million and $560 million. Adjusted
earnings per share target for the year has been revised to a band
of $1.60 and $1.70 from $1.55 to $1.65. However, Greatbatch has
retained its adjusted operating margin forecast of 12%-13%.
The current Zacks Consensus
Estimates for revenue and earnings per share for fiscal 2011 are
$568 million and $1.65, respectively.
Greatbatch is a leading producer
and supplier of batteries, capacitors and components used in
implantable medical devices. The company’s top customers include
Boston Scientific (BSX), Johnson &
Johnson (JNJ), Medtronic (MDT) and
St. Jude Medical (STJ).
Greatbatch has been acquiring
complementary businesses over the last few years to boost sales.
Moreover, the company continues to invest in developing medical
devices for its major OEM clients and spent $5.6 million on such
initiatives in
the second quarter. Greatbatch’s pipeline is healthy with a
number of products currently in
development that are expected to support growth in the long
run.
We feel that operating results for
the remainder of 2011 will be supported
by strength at the company’s Orthopedic business and strategic
investments. However, a soft CRM market and pricing
pressure
remain headwinds. Currently, we are Neutral on Greatbatch,
which is in line with a short-term Zacks #3 Rank (Hold).
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
GREATBATCH INC (GB): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024